Medical treatment of glaucoma: present and future

Bibliography

• Quigley H. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-93
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20
   PubMed Web of Science ®Google Scholar
• Konstas AG, Topouzis F, Leliopoulou O, 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. Ophthalmology 2006;113:761-5. e1
   PubMed Web of Science ®Google Scholar
• Lee AC, Mosaed S, Weinreb RN, Effect of laser trabeculoplasty on nocturnal intraocular pressure in medically treated glaucoma patients. Ophthalmology 2007;114:666-70
   PubMed Web of Science ®Google Scholar
• The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd edition. Editrice DOGMA S.r.l.; Savona, Italy: 2008
   Google Scholar
• van der Valk R, Webers CA, Schouten JS, Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Invernizzi T, Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566-73
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
   PubMed Web of Science ®Google Scholar
• Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third or fourth antiglaucoma medication effective?. J Glaucoma 2004;13:130-6
   PubMed Web of Science ®Google Scholar
• Teping C, Wiedemann B. The COMOD system. A preservative-free multidose container for eyedrops. Klin Monbl Augenheilkd 1994;205:210-17
   PubMed Web of Science ®Google Scholar
• Easty DL, Nemeth-Wasmer G, Vounatsos JP, Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol 2006;90:574-8
   PubMed Web of Science ®Google Scholar
• Rouland JF, Morel-Mandrino P, Elena PP, Timolol 0.1% gel (Nyogel 0.1% once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety. Ophthalmologica 2002;216:449-54
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Pillunat LE, Ropo A; on behalf of the Phase III Study Investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol 2010;88:12-19
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Chen E, Pfeiffer N, Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010;88:329-36
   PubMed Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010;27:837-45
   PubMed Web of Science ®Google Scholar
• Katz LJ, Cohen JS, Batoosingh AL, Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol 2010;149:661-671.e1
   PubMed Web of Science ®Google Scholar
• Manni G, Denis P, Chew P, The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2009;18:293-300
   PubMed Web of Science ®Google Scholar
• Shedden A, Adamsons IA, Getson AJ, Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2010;248:1757-64
   PubMed Web of Science ®Google Scholar
• Kaufman PL, Svedbergh B, Lutjen-Drecoll E. Medical trabeculocanalotomy in monkeys: with cytochalasin B or EDTA. Ann Ophthalmol 1979;11:795-7
   Web of Science ®Google Scholar
• Peterson JA, Tian B, Bershadsky AD, Latrunculin-A increases outflow facility in the monkey. Invest Ophthalmol Vis Sci 1999;40:931-41
   PubMed Web of Science ®Google Scholar
• Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 2001;42:1029-37
   PubMed Web of Science ®Google Scholar
• Waki M, Yoshida Y, Oka T, Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res 2001;22:470-4
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inatani M, Honjo M, Intraocular pressure–lowering effects and safety of topical administration of a selective ROCK inhibitor,SNJ-1656, in healthy volunteers. Arch Ophthalmol 2008;126:309-15
   PubMed Web of Science ®Google Scholar
• A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP). Available from: http://clinicaltrials.gov/ct2/show/NCT00902200. Last accessed 14 January 2011
   Google Scholar
• Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2003;44:1117-25
   PubMed Web of Science ®Google Scholar
• Pang IH, Fleenor DL, Hellberg PE, Aqueous outflow-enhancing effect of tert-butylhydroquinone: involvement of AP-1 activation and MMP-3 expression. Invest Ophthalmol Vis Sci 2003;44:3502-10
   PubMed Web of Science ®Google Scholar
• Lan YQ, Zhang C, Xiao JH, Suppression of IkappaBalpha increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells. Mol Vis 2009;15:1977-87
   PubMed Web of Science ®Google Scholar
• Crosson CE, Sloan CF, Yates PW. Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine. Invest Ophthalmol Vis Sci 2005;46:3795-9
   PubMed Web of Science ®Google Scholar
• Husain S, Shearer TW, Crosson CE. Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells. J Pharmacol Exp Ther 2007;320:258-65
   PubMed Web of Science ®Google Scholar
• Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Significantly Reduces Intraocular Pressure in Phase 1/2 Study. Available from: http://www.medicalnewstoday.com/articles/192124.php. Last accessed 14 January 2011
   Google Scholar
• A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01123785. Last accessed 14 January 2011
   Google Scholar
• Siegner SW, Netland PA, Schroeder A, Effect of calcium channel blockers alone and in combination with antiglaucoma medications on intraocular pressure in the primate eye. J Glaucoma 2000;9:334-9
   PubMed Web of Science ®Google Scholar
• Campana G, Bucolo C, Murari G, Ocular hypotensive action of topical flunarizine in the rabbit: role of s-1 recognition sites. J Pharmacol Exp Ther 2002;303:1086-94
   PubMed Web of Science ®Google Scholar
• Wang RF, Gagliuso DJ, Podos SM. Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys: J Glaucoma. 2008;17:73-8
   Google Scholar
• Abelson MB, Gilbert CM, Smith LM. Sustained reduction of intraocular pressure in humans with the calcium channel blocker verapamil. Am J Ophthalmol 1988;105:155-9
   PubMed Web of Science ®Google Scholar
• Abreu MM, Kim YY, Shin DH, Topical verapamil and episcleral venous pressure. Ophthalmology 1998;105:2251-5
   PubMed Web of Science ®Google Scholar
• Mansouri K, Silva SE, Shaarawy T. Efficacy and tolerability of topical 0.05% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study. J Glaucoma 2010
   PubMed Web of Science ®Google Scholar
• Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease. Available athttp://clinicaltrials.gov/ct2/show/NCT01254370. Last accessed 14 January 2011
   Google Scholar
• Ocular Hypotensive Efficacy of AR-102. Available from: http://clinicaltrials.gov/ct2/show/NCT00523250. Last accessed 14 January 2011
   Google Scholar
• Borghi V, Bastia E, Guzzetta M, A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J Ocul Pharmacol Ther 2010;26:125-32
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Millar CJ, Kiland JA, Effects of serotonergic compounds on aqueous humor dynamics in monkeys: Curr Eye Res. 2001;23:120-7
   Google Scholar
• Akaishi T, Takagi Y, Matsugi T, Effects of bunazosin hydrochloride on ciliary muscle constriction and matrix metalloproteinase activities. J Glaucoma 2004;13:312-18
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Kobayashi K, Okinami S. Efficacy of bunazosin hydrochloride 0.01% as adjunctive therapy of latanoprost or timolol. J Glaucoma 2004;13:73-80
   PubMed Web of Science ®Google Scholar
• Yoshikawa K, Katsushima H, Kimura T, Addition of or switch to topical bunazosin hydrochloride in elderly patients with normal-tension glaucoma: a one-year follow-up study. Jpn J Ophthalmol 2006;50:443-8
   PubMed Web of Science ®Google Scholar
• Tolerance and Effect on Intraocular Pressure After Administration of SYL040012. Available from: http://clinicaltrials.gov/ct2/show/NCT00990743. Last accessed 14 January 2011
   Google Scholar
• Merritt JC, Crawford WJ, Alexander PC, Effect of marijuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980;87:222-8
   PubMed Web of Science ®Google Scholar
• McIntosh BT, Hudson B, Yegorova S, Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol 2007;152:1111-20
   PubMed Web of Science ®Google Scholar
• Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc 2002;100:215-22; discussion 222-4
   PubMedGoogle Scholar
• Tomida I, Azuara-Blanco A, House H, Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 2006;15:349-53
   PubMed Web of Science ®Google Scholar
• Laine K, Jarvinen K, Mechoulam R, Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci 2002;43:3216-22
   PubMed Web of Science ®Google Scholar
• Jampel H. American glaucoma society position statement: marijuana and the treatment of glaucoma. J Glaucoma 2010;19:75-6
   PubMed Web of Science ®Google Scholar
• Granero GE, Longhi MR. Promising complexes of acetazolamide for topical ocular administration. Expert Opin Drug Deliv 2010;7:943-53
   PubMed Web of Science ®Google Scholar
• Gudmundsdottir E, Stefansson E, Bjarnadottir G, Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:3552-4
   PubMed Web of Science ®Google Scholar
• Shah GB, Sharma S, Mehta AA, Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol 2000;36:169-75
   PubMed Web of Science ®Google Scholar
• Lotti VJ, Pawlowski N. Prostaglandins mediate the ocular hypotensive action of the angiotensin converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys: J Ocul Pharmacol. 1990;6:1-7
   Google Scholar
• Loftsson T, Thorisdottir S, Fridriksdottir H, Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. Acta Ophthalmol 2010;88:337-41
   PubMed Web of Science ®Google Scholar
• Al-Sereiti MR, Turner P. Effect of captopril (an angiotensin-converting enzyme inhibitor) on intraocular pressure in healthy human volunteers. J Ocul Pharmacol 1989;5:1-5
   PubMedGoogle Scholar
• Costagliola C, Di Benedetto R, De Caprio L, Effect of oral captopril (SQ 14225) on intraocular pressure in man. Eur J Ophthalmol 1995;5:19-25
   PubMedGoogle Scholar
• Chiselita D, Vancea PP, Haulica I. The ocular hypotonic effect induced by an angiotensin-converting enzyme inhibitor (captopril). Oftalmologia 1996;40:18-25
   PubMedGoogle Scholar
• Wang RF, Podos SM, Mittag TW, Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res 2005;80:629-32
   PubMed Web of Science ®Google Scholar
• Costagliola C, Verolino M, De Rosa ML, Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects. Exp Eye Res 2000;71:167-71
   PubMed Web of Science ®Google Scholar
• Kaiser HJ, Graf T, Krejci G, A new angiotensin-II- receptor blocker, CGP 48933: local tolerance and effect on intraocular pressure. A pilot study. Eur J Ophthalmol 1997;7:35-9
   PubMedGoogle Scholar
• Vaajanen A, Vapaatalo H, Kautiainen H, Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye. Invest Ophthalmol Vis Sci 2008;49:2557-62
   PubMed Web of Science ®Google Scholar
• Zhang X, Clark AF, Yorio T. Interactions of endothelin-1 with dexamethasone in primary cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2003;44:5301-8
   PubMed Web of Science ®Google Scholar
• Thieme H, Stumpff F, Ottlecz A, Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 2001;42:3193-201
   PubMed Web of Science ®Google Scholar
• Thieme H, Schimmat C, Munzer G, Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 2006;47:938-45
   PubMed Web of Science ®Google Scholar
• Konno T, Maruichi M, Takai S, Effect of chymase on intraocular pressure in rabbits. Eur J Pharmacol 2005;524:132-7
   PubMed Web of Science ®Google Scholar
• Phillips CI, Green K, Gore SM, Eye drops of RU 486-6, a peripheral steroid blocker, lower intraocular pressure in rabbits. Lancet 1984;1:767-8
   PubMed Web of Science ®Google Scholar
• Zhang X, Krishnamoorthy RR, Prasanna G, Dexamethasone regulates endothelin-1 and endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells. Exp Eye Res 2003;76:261-72
   PubMed Web of Science ®Google Scholar
• Wiederholt M, Sturm A, Lepple WA. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci 1994;35:2515-20
   PubMed Web of Science ®Google Scholar
• Ito Y, Nagai N, Shimomura Y. Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-beta-cyclodextrin in rabbit. Biol Pharm Bull 2010;33:1574-8
   PubMed Web of Science ®Google Scholar
• Borghi V, Bastia E, Guzzetta M, A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J Ocul Pharmacol Ther 2010;26:125-32
   PubMed Web of Science ®Google Scholar
• Dortch-Carnes J, Russell KR. Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide. Pharmacology 2006;77(7):17-24
   PubMed Web of Science ®Google Scholar
• Rasmussen CA, Gabelt BT, Kaufman PL. Aqueous humor dynamics in monkeys: in response to the kappa opioid agonist bremazocine. Trans Am Ophthalmol Soc 2007;105:225-38; discussion 238-9
   PubMedGoogle Scholar
• Lee KC, Silver PJ, Bode DC, Ocular effects of topical administration of the phosphodiesterase III inhibitor milrinone in rabbits and cats. Methods Find Exp Clin Pharmacol 1993;15:527-34
   PubMed Web of Science ®Google Scholar
• Hoyng PF, Groeneboer MC, Busch MJ. Isobutylmethylxanthine enhances adrenergic-induced ocular hypotension in rabbits and beagles. Exp Eye Res 1991;52:511-17
   PubMed Web of Science ®Google Scholar
• Borras T, Gabelt BT, Klintworth GK, Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. J Gene Med 2001;3:437-49
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Hu Y, Vittitow JL, Caldesmon transgene expression disrupts focal adhesions in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments. Exp Eye Res 2006;82:935-44
   PubMed Web of Science ®Google Scholar
• Hu Y, Gabelt BT, Kaufman PL. Monkey organ-cultured anterior segments; technique and response to H-7. Exp Eye Res 2006;82:1100-8
   PubMed Web of Science ®Google Scholar
• Liu X, Hu Y, Filla MS, The effects of C3 transgene expression on actin and cellular adhesions in cultured human trabecular meshwork cells and on outflow facility in organ cultured monkey eyes. Mol Vis 2005;11:1112-21
   PubMed Web of Science ®Google Scholar
• Gerometta R, Spiga MG, Borras T, Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci 2010;51:3042-8
   PubMed Web of Science ®Google Scholar
• Spiga MG, Borras T. Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma. Invest Ophthalmol Vis Sci 2010;51:3029-41
   PubMed Web of Science ®Google Scholar
• Krupin T, Liebmann JM, Greenfield DS, A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011
   Google Scholar
• Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System. Available from: http://clinicaltrials.gov/ct2/show/NCT01080209. Last accessed 14 January 2011
   Google Scholar
• Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy. Available from: http://clinicaltrials.gov/ct2/show/NCT00693485. Last accessed 14 January 2011
   Google Scholar
• Schwartz M, Yoles E. Neuroprotection: a new treatment modality for glaucoma?. Curr Opin Ophthalmol 2000;11(2):107-11
   PubMedGoogle Scholar
• Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma?. Arch Ophthalmol 1999;117:1540-4
   PubMed Web of Science ®Google Scholar
• Koseki N, Araie M, Yamagami J, Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. J Glaucoma 1999;8:117-23
   PubMed Web of Science ®Google Scholar
• Koseki N, Araie M, Tomidokoro A, A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology 2008;115:2049-57
   PubMed Web of Science ®Google Scholar
• Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2010;2:CD006539
   PubMedGoogle Scholar
• DiMatteo MR, Giordani PJ, Lepper HS, Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40:794-811
   PubMed Web of Science ®Google Scholar
• Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 2005;16:114-21
   PubMedGoogle Scholar
• Tsai JC, McClure CA, Ramos SE, Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
   PubMed Web of Science ®Google Scholar
• Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996;7:80-6
   PubMedGoogle Scholar
• Martone G, Frezzotti P, Tosi GM, An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009;147:725-735.e1
   PubMed Web of Science ®Google Scholar
• Baudouin C, Liang H, Hamard P, The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008;115:109-15
   PubMed Web of Science ®Google Scholar
• De Saint Jean M, Brignole F, Bringuier AF, Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:619-30
   PubMed Web of Science ®Google Scholar
• Tielsch JM, Katz J, Sommer A, Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol 1995;113(2):216-21
   PubMed Web of Science ®Google Scholar
• Caprioli J, Coleman AL. Blood flow in glaucoma discussion. Blood pressure, perfusion pressure, and glaucoma. Am J Ophthalmol 2010;149:704-12
   PubMed Web of Science ®Google Scholar